I was part of their beta with CGM a long time ago. They were way behind Levels and their initial idea of training an AI on people with CGMs is not going to work in the end. There is way too much variability between people and between meals for glucose response prediction even if you enter exactly what you eat.
The order in which you eat/drink, the speed of eating, if/when you did a workout before/after, etc. makes it impossible to make any meaningful glucose prediction.

I switched to Levels. There is no substitute for a real CGM + calibration with fingerpick glucose.

I think it has a lot of potential - CarePods. In accordance with our mantra…test, test, test, anything that makes testing easier and cheaper is a good thing.
" And, making scans affordable for the masses, Forward’s competitive price point could encourage adoption beyond biohackers."
As long as they keep improving it with new tech and new tests.
“Aoun has ambitious plans for CarePods, and the company’s proven ability to iterate and develop new solutions shows it’s likely agile enough to work through early adopter issues. CarePods has a surprising number of features, and Forward Health will keep creating more.”

Here’s how it works: Users walk up to the door and unlock it with their mobile device. They step in alone and find a large touchscreen facing a chair. A glowing ring on the floor indicates the location of the full-body scanner. A hidden drawer on one of the sides delivers different medical tests as needed. A friendly female voice guides the patient through the process.

The CarePod’s screen serves up different apps available to the user: full body scan, heart health, thyroid testing, blood pressure, weight management, diabetes screening, COVID-19 test, HIV screening, kidney, and liver health — there seems to be an app for many ailments. Let’s say you pick heart health. The drawer opens and presents the patient with a sensor. The touchscreen instructs the user to place the sensor against their heart, and after a few tests, the diagnosis is displayed on the screen. And if more treatment is required, one of Forward’s doctors will review the findings in real time and issue a prescription or additional instructions.

Blood tests are performed with a single-use, needleless collection device. Blood pressure is measured using a wireless arm cuff. Skin testing uses a scanner. Various swabs are available to test for COVID-19, strep and other ailments. The company says it also tests for STDs but does not detail which type or how it completes the diagnosis.

Each CarePod is staffed with an attendant who can answer basic questions and services the device between uses.

After they get the kinks worked out, the attendant could probably be replaced on-screen with an AI chatbot and avatar. Should technically be able to do some simplified form of a DexaScan or VO2 Max test.
A CT scanner is too big and expensive to allow CAC tests but I wonder if they could invent some kind of automated, robotic machine to do CIMT tests. That would be great.
They could even have specialized cameras to do FaceAge or retina scanners to do RetinaAge and certainly could do eye tests and hearing tests. Or some functional tests like grip strength, balance or any number of others. Could be an easy stop in the mall to get your BioAge engraved on a little plaque that you could hang in your kitchen (certainly better than that damn plaque in your arteries!).

Well your friend needs to give me an invite code … Would love to sign up - but I’m not a member of the exclusive club with a code. I’d love to get one, and happy to give feedback. The use of AI searches is helping me in my work - it’s not the end all, but is doing things faster and better than the old way.

2 Likes

You can join the wait list here and they’ll give you access: Vera Health

Okay — I’m wait listed … so sad, never been wait listed before. Time to accept my position and identify with being a member of the proletariat.

3 Likes

A new AI tool based on research papers:

From: I'm troubled by something. Longevity Quotient and mTOR per cell, Please poke holes - #14 by RapAdmin

Elicit also looks good.

https://doctoraimd.com/elicit-ai-vs-consensus-ai-literature-reviews/

And here are some more that medical students use:

https://forums.studentdoctor.net/threads/gpt-4-and-medical-research-apps.1485558/

(https://drgupta.ai/)

(https://www.droracle.ai/)

(https://www.openevidence.com/)

And there’s this:

https://www.euronews.com/next/2024/01/20/best-ai-tools-academic-research-chatgpt-consensus-chatpdf-elicit-research-rabbit-scite

Which adds:
(https://scite.ai/)

(https://www.researchrabbit.ai/)

I think @desertshores is happy with Dr Oracle but if anyone has personal experience with the others and comparisons between them, let us know.

1 Like

I just tried it with the following tag.

metanalyses on berberine, last 5 years. Exclude papers form china

Alas, it included some papers from China, I’m wondering if there si a way around this, maybe just skip those results?

“form china” or “from china” - perhaps retry and see what happens, or try other boolean operators (“not china”, “exclude china”)…

The papers are not “from China” per se and I’m not sure the model takes into account the affiliations of the authors. You could try “Only include the highest quality evidence published in the best journals by the best researchers”.

1 Like

I retried but the AI seems to ignore the prompts to exclude china, not china, Chinese authors and so on. Maybe it has been trained to ignore potential racial suggestions!

I also pasted the longest sentence Only include the highest quality evidence published in the best journals by the best researchers. I don’t know how much the AI considered that, the caption for the results only included the 1st part of the enquiry ( Meta-analyses on Berberine from the Last 5 Years)

I assume that the AI has no idea what are good quality journals. The developers should take into account impact factor + number of citations of each paper.

Actually it seems to have something in that line, but it did not display these first. Maybe based on the context or on the specificity of the article.

image

2 Likes

China’s cheap, open AI model DeepSeek thrills scientists

A Chinese-built large language model called DeepSeek-R1 is thrilling scientists as an affordable and open rival to ‘reasoning’ models such as OpenAI’s o1.

These models generate responses step-by-step, in a process analogous to human reasoning. This makes them more adept than earlier language models at solving scientific problems and could make them useful in research. Initial tests of R1, released on 20 January, show that its performance on certain tasks in chemistry, mathematics and coding is on par with that of o1 — which wowed researchers when it was released by OpenAI in September.

“This is wild and totally unexpected,” Elvis Saravia, an AI researcher and co-founder of the UK-based AI consulting firm DAIR.AI, wrote on X.

R1 stands out for another reason. DeepSeek, the start-up in Hangzhou that built the model, has released it as ‘open-weight’, meaning that researchers can study and build on the algorithm. Published under an MIT licence, the model can be freely reused but is not considered fully open source, because its training data has not been made available.

https://www.nature.com/articles/d41586-025-00229-6?linkId=12623387&fbclid=IwY2xjawH_XfFleHRuA2FlbQIxMQABHd69QIqNJIzObiPPfGQU6GR9CtS8S8gLYBExdfLsMUvRaIsPP68ckFslrw_aem_Pyh_zG05s354OPOdjrWakg

4 Likes

Google’s Demis Hassabis on AI and Longevity (video queued up for this part of the discussion):

1 Like

RapAdmin, I would use it.

RapAdmin, I find ChatGPT to commonly have errors and presenting the same question at different times can give broadly different responses. If important I may run a question through other AI programs for verification.

Full article: Anthropic’s Dario Amodei Says A.I. Will Soon Double Human Lifespans | Observer

1 Like

By doing what, promoting resveratrol and vitamin E?

Manas AI, a cancer drug discovery startup co-helmed by LinkedIn founder Reid Hoffman, raised $24.6 million in funding.

Why it matters: Oncology represents a major area of opportunity when it comes to health tech investment.

Zoom in: Hoffman led the funding round with General Catalyst. Greylock, the VC firm where Hoffman was once a general partner, is also investing.

  • The startup will run its AI systems in data centers owned by Microsoft, where Hoffman is on the board of directors.
  • Hoffman started the company alongside cancer researcher and Columbia professor Siddhartha Mukherjee. Mukherjee is the author of “The Emperor of All Maladies” and cofounder of several biotech startups.

How it works: Manas will initially focus on breast cancer, prostate cancer and lymphoma, though it plans to broaden its scope to include more conditions, per the Wall Street Journal.

  • Mukherjee said he plans for the company “to make money primarily by developing and selling its own drugs.”

By the numbers: Research and drug discovery is flush with cash, especially during this era of AI bonanza.

  • In 2024, those types of companies received $3.34 billion in funding — five time more than in 2023, per PitchBook.

https://www.axios.com/pro/health-tech-deals/2025/01/27/reid-hoffman-led-manas-ai-nabs-25m-for-cancer-drug-discovery